Hélène Decaluwe

Dr. Hélène Decaluwe is a Canadian immunologist based in Montreal, Quebec.

Education

Decaluwe graduated from the Faculty of Medicine at McGill University and completed her residency in pediatrics at the CHU Sainte-Justine in partnership with the University of Montreal.

She then completed her training in pediatric clinical immunology at the Necker Enfants-Malades Hospital in Paris, France with Professor Alain Fischer. Her research training includes a Master and a PhD degree in immunology at Pierre and Marie Curie University carried out in the laboratories of Professor Jean-Laurent Casanova and Professor James Di Santo respectively.

Career and Affiliations

CHU Sainte-Justine

Associate Professor in the Immunology and Rheumatology Division of the CHU Sainte-Justine since 2010 and Clinician Scientist and outgoing Deputy Head of the Immune Diseases and Cancer Research Axis at the CHU Sainte-Justine Research Center.

National Advisory Committee on Immunization

Decaluwe is a member of the National Advisory Committee on Immunization (NACI).1)

Consulting

Decaluwe was invited in April 2021 by Eli Lilly to a Scientific Advisor Board on the role of baricitinib and monoclonal antibodies for the treatment of COVID-19.

Research

Decaluwe has dedicated her career to resolving the mechanisms of T cell differentiation in health, infection and primary immune deficiencies. The primary focus of her research is to better understand the role of cytokines in the differentiation of T cells in health and disease, and to develop novel immunotherapeutic approaches that target cytokine-dependent pathways and inhibitory receptors expressed on T cells, to cure chronic viral infections and cancer.

Funding

COVID-19

Decaluwe is a co-investigator on a research grant titled “Deciphering the immunopeptidomic landscape of COVID-19 disease” funded by the Canadian Institutes of Health Research through a COVID-19 project grant.3)

She has applied for the CIHR-CEPI Leadership Award for Excellence in Vaccine Research for Infectious Diseases of Epidemic Potential, administered by the Canadian Institutes of Health Research and Coalition for Epidemic Preparedness Innovations (CEPI).4)

RECOVER

Decaluwe is a co-investigator in the REinfection in COVid-19 Estimation of Risk (RECOVER study), alongside Caroline Quach-Thanh. The study is funded by the Canadian Institutes of Health Research, and the Public Health Agency of Canada through the COVID-19 Immunity Task Force.5) 6)

PITCH

Decaluwe is a co-Principal Investigator in the Persistence of T cell Immunity in Children with SARS-CoV-2 and Household contacts (PITCH Study), funded by the Children's Hospital Academic Medical Organization (CHAMO) innovation fund and the PSI Foundation.7)

CHOIR

Decaluwe is a Principal Investigator in the Children and Older Teens Immune Response to SARS-CoV-2 in Montreal (CHOIR study) alongside Caroline Quach-Thanh and Jesse Papenburg, funded by the Canadian Institutes of Health Research.8)

Presentations

Decaluwe presented at the 76th Annual Canadian Society of Allergy and Clinical Immunology Scientific Virtual Meeting on the topic of hyperinflammation and targeted immunotherapies in hemophagocytic lymphohistiocytosis.9)

1) , 4)
Public Health Agency of Canada. (2022, February 25). National Advisory Committee on Immunization (NACI): Membership and representation. Government of Canada. https://web.archive.org/web/20220318105951/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/naci-membership-representation.html#fn1-rf
2)
Swedish Orphan Biovitrum. (2022, April 7). A Two-cohort, Open-label, Single Arm, Multicenter Study to Evaluate Efficacy, Safety and Tolerability, PK and PD, of Emapalumab in Children and Adults With MAS in Still’s Disease or With MAS in Systemic Lupus Erythematous. ClinicalTrials.gov. https://archive.ph/03Dxx
3)
Canadian Institutes of Health Research. (2021, March 1). Deciphering the immunopeptidomic landscape of COVID-19 disease. Canadian Research Information System. https://archive.ph/RTsEd
5)
Racine, É., Boivin, G., Longtin, Y., McCormack, D., Decaluwe, H., Savard, P., Cheng, M. P., Hamelin, M.-È., Tadount, F., Adams, K., Bourdin, B., Nantel, S., Gilca, V., Corbeil, J., De Serres, G., & Quach, C. (2022). The REinfection in COVID-19 Estimation of Risk (RECOVER) study: Reinfection and serology dynamics in a cohort of Canadian healthcare workers. medRxiv, Preprint. https://doi.org/10.1101/2022.02.10.22269967
6)
Canadian Institutes of Health Research. (2020, June 1). REinfection in COVid-19 Estimation of Risk (RECOVER). Canadian Research Information System. https://archive.ph/3vdzt
7)
Decaluwe, H. Post-doctoral fellowship in COVID-19 Immunology CHU Sainte-Justine Research Center Title: T cell responses in COVID-19 patients following infection and/or vaccination. CHU Sainte-Justine Research Center. Retrieved May 22, 2022, from https://web.archive.org/web/20220522125556/https://research.chusj.org/RECHERCHE/files/71/717465d5-a2e8-42ac-8abf-509cb48c95b5.pdf
8)
Canadian Institutes of Health Research. (2021, December 1). CHOIR study: Children and Older Teens Immune Response to SARS-CoV-2 in Montreal. Canadian Research Information System. https://archive.ph/Dgq1p
9)
76th Annual Canadian Society of Allergy and Clinical Immunology Scientific Virtual Meeting. EMedEvents. Retrieved May 22, 2022, from https://www.emedevents.com/conferences/downloadbrochure/aHR0cHM6Ly93d3cuZW1lZGV2ZW50cy5jb20vdXBsb2Fkcy9jb25mZXJlbmNlcy9zZXNzaW9uX2Jyb2NodXJlLzhlNWM5Y2U0ZDBhYzMxNTI3YmQ4OTAzNDcwODJiMmY4LnBkZg==
Print/export